

S3 Table. Univariate and multivariate regression analyses

Outcome	Independent variable	Unit	Univariate		Multivariate	
			Regression coefficient (95% CI)	p-value	Regression coefficient (95% CI)	p-value
Overall survival	Induction therapy regimen	FP+oxaliplatin+Bev	5.32 (2.46 to 8.19)	< 0.001	0.68 (-5.07 to 6.43)	0.80
	Control: FP+oxaliplatin					
	Duration of induction therapy	1 week	-0.19 (-0.57 to 0.19)	0.31	0.11 (-0.40 to 0.62)	0.66
	Maintenance therapy regimen	FP or Bev	1.63 (-2.53 to 5.79)	0.42	2.77 (-0.13 to 5.68)	0.06
	Control: No treatment	FP+Bev	4.42 (0.15 to 8.70)	0.043	2.18 (-2.01 to 6.37)	0.28
	Oxaliplatin reintroduction rate	10%	0.88 (0.20 to 1.55)	0.013	0.25 (-0.90 to 1.40)	0.65
Progression-free survival ^{b)}	Maintenance therapy rate ^{a)}	10%	0.96 (0.59 to 1.32)	< 0.001	0.78 (0.16 to 1.40)	0.017
	Trial start year ^{a)}	1 year	1.12 (0.44 to 1.80)	0.003	0.33 (-0.32 to 0.97)	0.30
	Induction therapy regimen	FP+oxaliplatin+Bev	2.94 (1.18 to 4.70)	0.003	-0.30 (-2.15 to 1.55)	0.73
	Control: FP + oxaliplatin					
	Duration of induction therapy	1 week	-0.05 (-0.31 to 0.20)	0.66	0.08 (-0.06 to 0.23)	0.24
	Maintenance therapy regimen	FP or Bev	0.93 (-0.78 to 2.63)	0.27	1.41 (0.23 to 2.59)	0.023
	Control: No treatment	FP+Bev	4.48 (2.55 to 6.40)	< 0.001	3.73 (2.28 to 5.19)	< 0.001
	Maintenance therapy rate ^{a)}	10%	0.43 (0.18 to 0.69)	0.003	0.43 (0.16 to 0.70)	0.005

Bev, bevacizumab; CI, confidence interval; FP, fluoropyrimidine. ^{a)}Maintenance therapy rate for overall survival and progression-free survival and trial start year for overall survival were additionally used to adjust in the multivariate regression analysis, ^{b)}For 18 treatment arms recommended to continue maintenance therapy until disease progression.